Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rod-specific cGMP phosphodiesterase 6 (PDE6) is a key enzyme in the visual phototransduction cascade, primarily located in the outer segments of rod photoreceptor cells. It exists as a heterotetrameric complex consisting of two catalytic subunits (alpha and beta) and two inhibitory gamma subunits. Upon light stimulation, the G-protein transducin activates PDE6, which then rapidly hydrolyzes cyclic guanosine monophosphate (cGMP) to 5'-GMP. This decrease in cGMP levels leads to the closure of cGMP-gated cation channels, resulting in cell hyperpolarization and the transmission of visual signals to the brain. Mutations in the genes encoding its subunits (PDE6A, PDE6B, or PDE6G) are a major cause of autosomal recessive retinitis pigmentosa, a degenerative eye disease characterized by night blindness and progressive peripheral vision loss. Additionally, PDE6 is a significant off-target for phosphodiesterase 5 (PDE5) inhibitors like sildenafil, which can cause transient visual disturbances due to their structural similarity to the PDE6 catalytic site.
Phosphodiesterase inhibition; Gene supplementation
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rod-specific cGMP phosphodiesterase 6 (PDE6).